Literature DB >> 6102031

Disposition of all-trans- and 13-cis-retinoic acids and n-hydroxyethylretinamide in mice after intravenous administration.

C C Wang, S Campbell, R L Furner, D L Hill.   

Abstract

The disposition of 13-cis- and all- trans-retinoic acids and N-hydroxyethylretinamide has been studied in mice after an intravenous dose of 10 mg/kg. As determined by high-ressure liquid chromatography, serum levels of 13-cis-retinoic acid, in a distribution phase, decreased rapidly over a 30-min period. This was followed by an apparently exponential phase of elimination. N-Hydroxyethylretinamide had a distribution phase lasting for 1 hr followed by an exponential phase. All-trans-retinoic acid had a similar distribution phase, but this was followed by a nonexponential phase. Tissue levels of 13-cis-retinoic acid, although generally not as high as those in serum, decreased in a manner similar to that for serum. Levels of all-trans-retinoic acid in liver, kidney, lung, brain, and small intestine were generally higher than those of serum throughout the period of observation. At 8 hr after injection of the mice, relatively high levels of all-trans-retinoic acid remained in the brains, and detectable levels of 13-cis-retinoic acid persisted in the lungs. N-Hydroxyethylretinamide also persisted in tissues for long periods of time, with tissue levels generally higher than those in serum. At 18 hr after injection of mice, relatively high levels of this compound were found in the liver, kidneys, and testes.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6102031

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  6 in total

1.  Computation of log BB values for compounds transported through carrier-mediated mechanisms using in vitro permeability data from brain microvessel endothelial cell (BMEC) monolayers.

Authors:  Helen H Usansky; Patrick J Sinko
Journal:  Pharm Res       Date:  2003-03       Impact factor: 4.200

2.  Physiologically Based Pharmacokinetic Model of All-trans-Retinoic Acid with Application to Cancer Populations and Drug Interactions.

Authors:  Jing Jing; Cara Nelson; Jisun Paik; Yoshiyuki Shirasaka; John K Amory; Nina Isoherranen
Journal:  J Pharmacol Exp Ther       Date:  2017-03-08       Impact factor: 4.030

3.  Retinoic acid attenuates beta-amyloid deposition and rescues memory deficits in an Alzheimer's disease transgenic mouse model.

Authors:  Yun Ding; Aimin Qiao; Ziqing Wang; J Shawn Goodwin; Eun-Sook Lee; Michelle L Block; Matthew Allsbrook; Michael P McDonald; Guo-Huang Fan
Journal:  J Neurosci       Date:  2008-11-05       Impact factor: 6.167

Review 4.  Clinical pharmacokinetics of the retinoids.

Authors:  R W Lucek; W A Colburn
Journal:  Clin Pharmacokinet       Date:  1985 Jan-Feb       Impact factor: 6.447

5.  A novel intergenic ETnII-β insertion mutation causes multiple malformations in polypodia mice.

Authors:  Jessica A Lehoczky; Peedikayil E Thomas; Kevin M Patrie; Kailey M Owens; Lisa M Villarreal; Kenneth Galbraith; Joe Washburn; Craig N Johnson; Bryant Gavino; Alexander D Borowsky; Kathleen J Millen; Paul Wakenight; William Law; Margaret L Van Keuren; Galina Gavrilina; Elizabeth D Hughes; Thomas L Saunders; Lesil Brihn; Joseph H Nadeau; Jeffrey W Innis
Journal:  PLoS Genet       Date:  2013-12-05       Impact factor: 5.917

6.  Retinoic Acid Induces an IFN-Driven Inflammatory Tumour Microenvironment, Sensitizing to Immune Checkpoint Therapy.

Authors:  Caitlin M Tilsed; Thomas H Casey; Emma de Jong; Anthony Bosco; Rachael M Zemek; Joanne Salmons; Graeme Wan; Michael J Millward; Anna K Nowak; Richard A Lake; Willem Joost Lesterhuis
Journal:  Front Oncol       Date:  2022-03-24       Impact factor: 6.244

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.